30 articles tagged with #drug-discovery. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
NVIDIA CEO Jensen Huang participated in a fireside chat at the J.P. Morgan Healthcare Conference, discussing AI applications across healthcare sectors including genomic research, drug discovery, clinical trials, and patient care. The discussion highlighted how AI is making significant inroads throughout the entire healthcare industry.
Researchers have developed FlexMS, a flexible benchmark framework for evaluating deep learning models that predict mass spectra for molecular identification in drug discovery and material science. The framework addresses current challenges in assessing different prediction approaches by providing standardized evaluation methods and insights into performance factors across various model architectures.
Drug-resistant infections are increasing due to antibiotic overuse and misuse, while development of new antibacterial treatments has slowed. Synthetic biology and AI are being explored as potential solutions to address the growing global antimicrobial resistance threat.
Professor James Collins discusses how collaboration has been central to his research combining computational predictions with experimental platforms to accelerate therapeutic drug discovery and design using AI technologies.
The article title suggests SAIR is leveraging AI technology to accelerate pharmaceutical research and development through structural intelligence capabilities. However, without the article body content, specific details about the technology, partnerships, or market impact cannot be analyzed.
